Institute for Clinical and Economic Review (ICER) VS. Health Technology Assessment (HTA) Agencies: The Case of Multiple Myeloma and PCSK9S

ICER, a newly established HTA organization in the U.S., has been both praised and criticized for its drug assessments. Manufacturers and patient groups have been critical of ICER, but is this criticism justified? ICER’s goal is similar to other established HTA agencies: to inform payers and policymakers on a drug’s value and better tie drug prices to value. How does the ICER’s decisions compare to those of more established HTA agencies? We...